Pharma excipients manufacturer AVT has been cultivating the market of high- end complex injection in China for more than ten years, and has been cooperating with domestic R&D and production companies, universities as well as research institutes on various types of complex injection for many years. Our injectable excipients are widely used in marketed liposomes, fat emulsion formulations and biological formulations as well as in the research and development of these new drugs. As a reliable pharma excipients supplier, the quality and safety of our various types of  pharmaceutical excipients are trustworthy.
 

Types of Pharmaceutical Excipients

Biopharmaceutical Excipients

AVT strives to provide low-endotoxin excipients used in injections that meet urgent needs of biopharmaceutical development. The quality of different types of excipients in pharma conforms to USP, EP, JP standards, and has been registered in US FDA with DMF number.

Liposome Excipients

As pharma excipients manufacturer, we provide multi-species, injectable and high-purity for lipo-some drug development; our production base meets GMP requirements for pharma excipients market and can receive audits from various countries; we have a complete range of liposome excipients to meet the needs of different customers for types of excipients used in pharmaceutical industry and can provide customized pharmaceutically acceptable excipient services.

Fat Emulsion Excipients

We provide cost-effective lecithins and oleic acid excipients for the devel-opment and production of fat emulsion drugs; The production base meets GMP requirements for excipient manufacturing; product quality complies with USP, EP and JP stan-dards, all excipients are injectable excipients; We have suficient production capacity with annual output of types of excipients around 50 to 300 tons to meet your demands.

Lipid nanoparticles（LNPs）

lipid nanoparticles (LNPs), are nanoparticles composed of lipids (including cationic lipid、phospholipid、PEG-lipid and helper lipid). They are the most clinically advanced non-viral gene delivery system for Intracellular Delivery of Nucleic Acid Therapeutics. LNPs as a drug delivery vehicle were first approved in 2018 for the siRNA drug Onpattro. Currently in the spotlight as vital components of the COVID-19 mRNA vaccines (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines), LNPs play a key role in effectively protecting and transporting mRNA to cells.